Evidence map›Paper›PMID 25712342›Full record

ArticleCancer research2015

FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells.

Runhua Liu, Cong Liu, Dongquan Chen, Wei-Hsiung Yang, Xiuping Liu, Chang-Gong Liu, Courtney M Dugas, Fei Tang, Pan Zheng, Yang Liu and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Identification of FOXP3American journal of physiology. Cell physiology · 2024
    Article
  16. miR-146a inhibits ovarian tumor growthMolecular therapy oncolytics · 2023
    Article
  17. Review
  18. Article
  19. Review
  20. Observational

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Runhua LiuDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. lwang12@uab.edu runhua@uab.edu.
Cong LiuDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama. Department of Endocrinology, ShengJing Hospital of China Medical University, Shenyang, PR China.
Dongquan ChenDivision of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Wei-Hsiung YangDepartment of Biomedical Sciences, Mercer University School of Medicine, Savannah, Georgia.
Xiuping LiuDepartment of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Chang-Gong LiuDepartment of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Courtney M DugasDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
Fei TangCenter for Cancer and Immunology Research, Children's National Medical Center, Washington, District of Columbia.
Pan ZhengCenter for Cancer and Immunology Research, Children's National Medical Center, Washington, District of Columbia.
Yang LiuCenter for Cancer and Immunology Research, Children's National Medical Center, Washington, District of Columbia.
Lizhong WangDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. lwang12@uab.edu runhua@uab.edu.
University of Alabama at Birmingham · US

Funding

TRAINING AND CAREER DEVELOPMENTU54CA118948 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Timiya S Nolan · 2005 to 2026
$26.6M
UAB CANCER RESEARCH EXPERIENCES FOR STUDENTS(CARES)R25CA076023 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SMITH, PETER R., WATERBOR, JOHN W · 1999 to 2020
$5.6M
MicroRNAs for monitoring tumor progression and predicting response to therapyR21CA179282 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WANG, LIZHONG · 2014 to 2015
$352k
FOXP3-microRNA146-NFkB Axis in Tumor SuppressionR21CA164688 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WANG, LIZHONG · 2012 to 2013
$341k
NCI NIH HHS CA118948NCI NIH HHS CA164688NCI NIH HHS CA179282NCI NIH HHS R21 CA164688NCI NIH HHS R21 CA179282NCI NIH HHS R25 CA076023NCI NIH HHS U54 CA118948
6 · The paper itself

Abstract

FOXP3 functions not only as the master regulator in regulatory T cells, but also as an X-linked tumor suppressor. The tumor-suppressive activity of FOXP3 has been observed in tumor initiation, but its role during tumor progression remains controversial. Moreover, the mechanism of FOXP3-mediated tumor-suppressive activity remains largely unknown. Using chromatin immunoprecipitation (ChIP) sequencing, we identified a series of potential FOXP3-targeted miRNAs in MCF7 cells. Notably, FOXP3 significantly induced the expression of miR-146a/b. In vitro, FOXP3-induced miR-146a/b prevented tumor cell proliferation and enhanced apoptosis. Functional analyses in vitro and in vivo revealed that FOXP3-induced miR-146a/b negatively regulates NF-κB activation by inhibiting the expression of IRAK1 and TRAF6. In ChIP assays, FOXP3 directly bound the promoter region of miR-146a but not of miR-146b, and FOXP3 interacted directly with NF-κB p65 to regulate an miR-146-NF-κB negative feedback regulation loop in normal breast epithelial and tumor cells, as demonstrated with luciferase reporter assays. Although FOXP3 significantly inhibited breast tumor growth and migration in vitro and metastasis in vivo, FOXP3-induced miR-146a/b contributed only to the inhibition of breast tumor growth. These data suggest that miR-146a/b contributes to FOXP3-mediated tumor suppression during tumor growth by triggering apoptosis. The identification of a FOXP3-miR-146-NF-κB axis provides an underlying mechanism for disruption of miR-146 family member expression and constitutive NF-κB activation in breast cancer cells. Linking the tumor suppressor function of FOXP3 to NF-κB activation reveals a potential therapeutic approach for cancers with FOXP3 defects.

Indexed as

Feedback, PhysiologicalAnimalsApoptosisBreast NeoplasmsDown-RegulationFemaleForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceMice, Inbred NODMice, TransgenicMicroRNAsNF-kappa BTumor Cells, CulturedForkhead Transcription FactorsFOXP3 protein, humanMicroRNAsMIRN146 microRNA, humanNF-kappa B

Identifiers

PMID25712342
PMCPMC4706751
OpenAlexW2148205338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.